General Information of Drug (ID: DMCNTFW)

Drug Name
Ad-RTS-hIL-12 Drug Info
Indication
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Phase 2 [1]
Melanoma 2C30 Phase 2 [2]
Recurrent glioblastoma 2A00.00 Phase 2 [3]
Malignant glioma 2A00.0 Phase 1 [4]
Cross-matching ID
TTD Drug ID
DMCNTFW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Interleukine 12 (IL-12)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABP 654 DM0GXWT Plaque psoriasis EA90.0 Phase 3 [6]
GEN-1 DMJN09S Ovarian cancer 2C73 Phase 2 [7]
Tavokinogene telseplasmid DMZX0VF Melanoma 2C30 Phase 2 [8]
MEDI1191 DMD9OVI Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
M9241 DMZUM67 Pancreatic cancer 2C10 Phase 1 [10]
YH010 DMA1T66 Aggressive cancer 2A00-2F9Z Investigative [11]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukine 12 (IL-12) TTG68FB IL12A_HUMAN; IL12B_HUMAN Replacement [5]

References

1 ClinicalTrials.gov (NCT04006119) Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma. U.S. National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033476)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of Ziopharm Oncology.
6 Clinical pipeline report, company report or official report of Amgen
7 Clinical pipeline report, company report or official report of Celsion.
8 Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Apr;31(4):532-540.
9 Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298.
10 Clinical pipeline report, company report or official report of EMD Serono.
11 Clinical pipeline report, company report or official report of Biocytogen